Citi resumed coverage of Medline (MDLN) with a Buy rating and $60 price target following a period of suspension. The company’s Q4 report came in well ahead of expectations on broad-based strength, the analyst tells investors in a research note. Citi believes Medline has a “compelling set-up” into fiscal 2026 as a “safety trade.”
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
